Cidara Therapeutics Announces Oral Presentations on Rezafungin at Two Upcoming Global Conferences
Cidara Therapeutics, Inc. (CDTX)
Last cidara therapeutics, inc. earnings: 3/4 05:55 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cidara.com
Company Research
Source: Business Wire
Data Will Highlight Potential Advantages of Rezafungin for the Treatment and Prevention of Invasive Fungal Infections SAN DIEGO--(BUSINESS WIRE)-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Dr. Taylor Sandison, chief medical officer, will present clinical efficacy and safety data for the company’s lead antifungal rezafungin for the treatment and prevention of invasive fungal infections at two upcoming, global infectious disease conferences. Abstracts highlighting rezafungin data have been accepted at The 20th International Immunocompromised Host Society (ICHS) Symposium in Athens, Greece, taking place June 17-19, 2018, and The International Society for Human and Animal Mycology (ISHAM) Congress in Amsterdam, taking place in The Netherlands, June 30-July 4, 2018. The ICHS Symposium is an interna
Show less
Read more
Impact Snapshot
Event Time:
CDTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDTX alerts
High impacting Cidara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CDTX
News
- Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]Yahoo! Finance
- Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024GlobeNewswire
- Steven Cohen's Point72 Adds Cidara Therapeutics to Its Portfolio [Yahoo! Finance]Yahoo! Finance
- Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO [Yahoo! Finance]Yahoo! Finance
- Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYOGlobeNewswire
CDTX
Earnings
- 11/2/23 - Beat
CDTX
Sec Filings
- 3/20/24 - Form 4
- 3/20/24 - Form 4
- 3/20/24 - Form 4
- CDTX's page on the SEC website